ClinicalTrials.Veeva

Menu

Mucosal Barrier Defects in Functional Dyspepsia by Confocal Laser Endomicroscopy

S

Shandong University

Status

Unknown

Conditions

Functional Dyspepsia

Study type

Observational

Funder types

Other

Identifiers

NCT01006642
2009SDU-QILU-G04

Details and patient eligibility

About

There has been recent interest into the potential role of mucosal barrier defects in the pathophysiology of functional gastrointestinal disorders (FGIDs). There has been evidence of increased intestinal permeability in patients of IBS,and abnormal tissue resistance in NERD. Although the mucosa of Functional dyspepsia (FD) patients is endoscopically and histologically "normal," it contains ultrastructural changes, activated immune cells, along with evidence of an increased release of mediators leading to gastric dysfunction. There is now consistent evidence indicating that mucosal barrier defects allow the passage of an increased load of bacteria, antigens and toxins which, in turn evoke activation of mucosal immune responses involved in the FD symptom.

Full description

Confocal laser endomicrosopy is a newly developed device which allows in vivo and real time observation of gastrointestinal mucosa.In our pilot study we found that the contrast agent fluorescein sodium shew differences of leakage into intercellular spaces and crypt lumen among different patients of FD.

This study is aimed to determine if there is microscopic changes detectable in the gastric mucosal epithelium through confocal endomicroscopy of FD patients, and to evaluate the relationship among minimal changes(transmission electron microscopy and Confocal laser endomicrosopy ), FD symptoms(symptom index form) , neuropeptides and immune responses(immunohistochemistry).

Enrollment

80 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • patients meeting IBS diagnosis criteria and indications for endoscopy investigation.
  • Asymptomatic individuals for health surveillance or patients for follow up after polypectomy.

Exclusion criteria

  • Esophageal, gastric or duodenal cancer or other malignancy
  • History of esophagus, stomach, or duodenum surgery
  • Conditions that preclude safe biopsies (coagulopathy, haemophilia, esophageal varices,and patients on warfarin and antiplatelets)
  • A history of bronchial asthma, or known allergy to fluorescein
  • Pregnant or breast-feeding (for females)
  • Below 18 or above 75 years of age
  • Severe co-morbidities
  • Unable or unwilling to give informed consent

Trial design

80 participants in 3 patient groups

Healthy controls
Description:
Asymptomatic individuals admitted for health surveillance or patients for follow up after polypectomy.
Functional dyspepsia-EPS
Description:
Functional dyspepsia-EPS(epigastric pain syndrome) Patients admitted to outpatient department with symptoms meeting ROME III criteria
Functional dyspepsia-PDS
Description:
Functional dyspepsia-PDS(postprandial distress syndrome) Patients admitted to outpatient department with symptoms meeting ROME III criteria

Trial contacts and locations

1

Loading...

Central trial contact

Yanqing Li, PhD. MD.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems